✨ Free AI Report
AC Immune AG: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research AC Immune AG
Company Research

AC Immune AG: Business Overview, Financials & Competitive Analysis

AC Immune AG scores 6/10 on the AskCyborg Cyborg Score (Solid). AC Immune represents a focused play on neurodegeneration therapies with differentiated technology and strategic partnerships, but success depends on clinical trial outcomes. AC Immune demonstrates solid scientific leadership in a high-value therapeutic area with meaningful partnerships, though clinical-stage development carries inherent risk and the company faces intense competition in.

What is AC Immune AG's industry? AC Immune AG (acimmune.com) operates in Biopharmaceuticals - Neurodegenerative Diseases / Immunotherapy. AskCyborg classifies AC Immune AG under Biopharmaceuticals - Neurodegenerative Diseases / Immunotherapy in its company registry.

AC Immune is a Swiss-based biopharmaceutical company focused on developing immunotherapies for neurodegenerative diseases, particularly Alzheimer's disease. The company leverages its proprietary SupraAntigen and Morph...

6/ 10Solid

Cyborg Score thesis

AC Immune represents a focused play on neurodegeneration therapies with differentiated technology and strategic partnerships, but...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Neurodegenerative Diseases / Immunotherapy
3 named competitors
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest AC Immune AG Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for AC Immune AG

AskCyborg analysts argue the bull and bear cases for AC Immune AG across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
AC Immune AG OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

AC Immune AG Overview

Pro stress-test →

AC Immune is a Swiss-based biopharmaceutical company focused on developing immunotherapies for neurodegenerative diseases, particularly Alzheimer's disease. The company leverages its proprietary SupraAntigen and Morphomer technology platforms to develop disease-modifying treatments.

Strategic Profile

Pro stress-test →

AC Immune positions itself as a pioneer in neuroinflammation and tau-targeting therapeutics. The company operates through partnerships with major pharmaceutical firms and maintains a robust pipeline of clinical-stage candidates aimed at slowing or halting cognitive decline in Alzheimer's disease.

Competitive Landscape

Pro stress-test →

AC Immune competes with major biotech and pharma firms developing Alzheimer's treatments including Eli Lilly, Roche, Biogen, and Novartis. Its differentiation lies in its tau-targeting and immunotherapy approaches within a crowded neurodegeneration space.

Industry Context

AC Immune AG operates in Biopharmaceuticals - Neurodegenerative Diseases / Immunotherapy.

Key facts

Founded: 2003 · Headquarters: Zug, Switzerland

What the analysts stress-tested

The top findings that survived the multi-agent debate for AC Immune AG.

  • Specializes in tau and neuroinflammation pathways for Alzheimer's disease, a major unmet medical need
  • Maintains strategic partnerships with large pharma companies for development and commercialization
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Lecanemab (Leqembi)Anti-amyloid monoclonal antibody for Alzheimer's→AducanumabPreviously approved Alzheimer's therapeutic→GLP-1 agonistsEmerging applications in neurodegenerative disease→

Compare AC Immune AG with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

AC Immune AG operates in Biopharmaceuticals - Neurodegenerative Diseases / Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Neurodegenerative Diseases / Immunotherapy research →
NEW · MCP server

Ask your AI assistant about AC Immune AG

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare AC Immune AG and its top competitor on Cyborg Score”
“What did AC Immune AG do this quarter?”
“Is AC Immune AG a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does AC Immune AG do?+
AC Immune is a Swiss-based biopharmaceutical company focused on developing immunotherapies for neurodegenerative diseases, particularly Alzheimer's disease. The company leverages its proprietary SupraAntigen and Morph...
What is AC Immune AG's Cyborg Score?+
AC Immune AG has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are AC Immune AG's main competitors?+
Named competitors include Lecanemab (Leqembi), Aducanumab, GLP-1 agonists. The full competitive landscape is in the AskCyborg report.
How can I get the full AC Immune AG research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the AC Immune AG research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track AC Immune AG over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Neurodegenerative Diseases research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Acumen Pharmaceuticals, Inc.